Paragon 28, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 08, 2024 at 04:05 pm EDT
Share
Paragon 28, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 61.08 million compared to USD 52.04 million a year ago. Net loss was USD 15.23 million compared to USD 9.05 million a year ago.
Paragon 28, Inc. is a medical device company focused on the foot and ankle orthopedic market. The Company provides orthopedic solutions, procedural approaches and instrumentation that cover a range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, it provides a portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Its broad suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. It has developed a comprehensive portfolio of foot and ankle surgical systems. Each system typically includes plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables specifically designed for the particular surgical system.